Epizyme’s Cancer Drug Studies to Continue; Some Tumors Wiped Out
A picture taken on March 14, 2016 shows tablets and capsules in Paris displayed on a desktop for an illustration in Paris. / AFP / FRANCK FIFE (Photo credit should read FRANCK FIFE/AFP/Getty Images)
Photographer: FRANCK FIFE/AFP/Getty ImagesEpizyme Inc. said four groups of patients with persistent cases of a blood cancer responded well enough to its drug to keep the company’s studies going, and some patients taking the medication saw their tumors wiped out.
A statistical assessment of the four groups treated with Epizyme’s drug for non-Hodgkin lymphoma showed that responses were strong enough to continue, the company said Sunday in a statement. The trial is looking at the drug, called tazemetostat, in patients with different types of the disease who relapsed after taking other therapies. More data is needed to decide whether to continue the trial in a fifth patient group, the company said.